Newsroom News Archive Publications Contact Us for Experts
Media Contacts
Susanne Hartman
(215) 349-5964

Related Links
Perelman School of Medicine
University of Pennsylvania Health System

Recommend Story
> Epigenetics Shapes Fate of Brain vs. Brawn Castes in Carpenter Ants
> Molecular Master Switch for Pancreatic Cancer Identified, Potential Predictor of Treatment Outcome
> Eat to Dream: Penn Study Shows Dietary Nutrients Associated with Certain Sleep Patterns
  All News Releases
    Media Resources
spacerspacerNEWS RELEASE spacer Print Version
FEBRUARY 19 , 2007
  46-Year-Old Man Receives First Temporary Total Artificial Heart in Northeast U.S. From Penn Cardiac Surgeons
  New “Bridge to Transplant” Technology Used to Lengthen Lives of Patients Waiting for Donor Human Hearts

UPDATE: Patient Gary Onufer received a donor heart on March 11, 2007. His recovery went well and he was discharged from the Hospital of the University of Pennsylvania on March 22, 2007.

(PHILADELPHIA) — A 46-year-old former fitness instructor, suffering from biventricular end-stage heart failure and in irreversible cardiogenic shock, has become the first to receive a new temporary Total Artificial Heart in the Northeast U.S. by cardiac surgeons at the University of Pennsylvania Health System.

CardioWest Temporary Total Artificial Heart

The Temporary Total Artificial Heart

Click on thumbnail
to view full-size image

The lifesaving technology is used as a “bridge to transplant” for patients who are waiting for a donor human heart and who have both sides of their heart failing, do not respond to other treatments and are at imminent risk of death. Research has shown that patients receiving the device, called the temporary Total Artificial Heart (TAH-t) and manufactured by CardioWest™ (SynCardia Systems, Inc.), have almost twice the survival rate versus patients who received standard ventricular assist devices.

Rohinton Morris, MD, Surgical Director, Heart Transplantation and Mechanical Assist Programs at Penn, and his team performed Penn’s first implant of a TAH-t on February 12, 2007, making Penn a certified transplant center for the new therapy. The patient, Ambler, PA resident, Gary Onufer, is said to be doing well following Monday’s six hour surgery. The TAH-t completely replaced his damaged heart, as opposed to just assisting it, while he waits for a donor heart to become available for transplant. Prior to the surgery, Onufer’s heart could no longer pump enough blood to sustain his body, damaging his vital organs.

Diagram of Implanted Temporary Total Artificial Heart

Diagram of Implanted Temporary Total Artificial Heart

Click on thumbnail
to view full-size image

Morris comments, “This unique new cardiac technology keeps the sickest of the sick – those with damage to their entire heart muscle – alive while they wait for a heart transplant. This is just the latest addition to our already wide arsenal in battling the nation’s number one killer, heart disease. We at Penn are dedicated to pioneer and lead in the field of heart transplantation and mechanical assist devices.”

The TAH-t is a modern version of the Jarvik-7 Artificial Heart that was implanted in patient Barney Clark in 1982. After ten years of study, the TAH-t is now the only total artificial heart approved by the U.S. Food and Drug Administration, Health Canada and Communite Europeenne for “bridge to transplant.”

Operation of the Temporary Total Artificial Heart
Double-click on screenshot to play animation
Courtesy of SynCardia Systems, Inc.

Michael Acker, MD, Chief, Division of Cardiac Surgery at Penn, adds, “The TAH-t pumps up to 9.5 liters of blood per minute through both ventricles – making it the highest cardiac output of all mechanical circulatory support devices. This is truly lifesaving technology, implanted to do the work of a failing human heart until another one becomes available.

Penn joins a short, prestigious list of institutions worldwide – becoming the first hospital in the region, 8th in the country, and 15th in the world – to complete TAH-t certification by performing a first proctored implant.

Proceeds of more than $700,000 from the 2006 Philadelphia Antiques Show went to fund new technologies, including total artificial heart pumps, supporting consoles, and monitoring equipment in the Heart Transplantation and Mechanical Assist Program in the Division of Cardiac Surgery at Penn.

Editor's Note: Drs. Rohinton Morris and Michael Acker have no financial interest in CardioWest™ or SynCardia Systems, Inc.


PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.


About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2016, The Trustees of the University of Pennsylvania